sk&f-38393 has been researched along with Cardiac Failure in 10 studies
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine: A selective D1 dopamine receptor agonist used primarily as a research tool.
1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol : A benzazepine that is 2,3,4,5-tetrahydro-3-benzazepine bearing a phenyl substituent at position 1 and two hydroxy substituents at positions 7 and 8.
SKF 38393 : A racemate comprising equimolar amounts of (R)- and (S)-SKF 38393
| Excerpt | Relevance | Reference |
|---|---|---|
| "Eighteen patients with New York Heart Association class III congestive heart failure were given single 100 mg oral doses of fenoldopam with food or fasting in a random-order single-blind crossover trial." | 9.07 | The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. ( Blanchett, DG; Boyle, DA; Corder, CN; Cyronak, MJ; Green, JA; Jarvis, RC; Kasmer, RJ; Nara, A; Pospisil, R, 1991) |
| "To determine the maintenance of pharmacodynamic effects of fenoldopam mesylate, a dopamine-1 agonist, the invasive hemodynamic profiles of 33 patients with New York Heart Association functional class III to IV congestive heart failure were examined." | 7.68 | Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure. ( Benotti, JR; Green, JA; Jarvis, RC; Kasmer, RJ; McCue, JE; Munger, MA; Nara, AR; Pospisil, RA, 1990) |
| "The potential interaction between fenoldopam, a DA1 selective agonist, and digoxin has been studied in 10 patients with heart failure (NYHA Class II or III) on chronic digoxin treatment." | 7.67 | Interaction study of fenoldopam--digoxin in congestive heart failure. ( Ambrosioni, E; Fuccella, LM; Malini, PL; Pasinelli, F; Riva, E; Strocchi, E; Tartagni, F; Valtancoli, G, 1989) |
| " A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug." | 6.38 | Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989) |
| "Eighteen patients with New York Heart Association class III congestive heart failure were given single 100 mg oral doses of fenoldopam with food or fasting in a random-order single-blind crossover trial." | 5.07 | The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure. ( Blanchett, DG; Boyle, DA; Corder, CN; Cyronak, MJ; Green, JA; Jarvis, RC; Kasmer, RJ; Nara, A; Pospisil, R, 1991) |
| "The effects of chronic oral fenoldopam in the treatment of NYHA grade II-III heart failure secondary to ischaemic heart disease, were studied in a placebo controlled, double blind, randomised, parallel group fashion in 20 patients." | 5.06 | A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease. ( Jeffrey, RF; Lee, MR; MacDonald, TM; Muir, AL, 1990) |
| " The novel DA1 receptor agonist fenoldopam is claiming a role in the management of hypertension, heart failure, and the preservation of renal function." | 4.78 | Dopamine and dopamine receptor agonists in cardiovascular therapy. ( Elliott, WJ; Murphy, MB, 1990) |
| "To determine the maintenance of pharmacodynamic effects of fenoldopam mesylate, a dopamine-1 agonist, the invasive hemodynamic profiles of 33 patients with New York Heart Association functional class III to IV congestive heart failure were examined." | 3.68 | Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure. ( Benotti, JR; Green, JA; Jarvis, RC; Kasmer, RJ; McCue, JE; Munger, MA; Nara, AR; Pospisil, RA, 1990) |
| "The potential interaction between fenoldopam, a DA1 selective agonist, and digoxin has been studied in 10 patients with heart failure (NYHA Class II or III) on chronic digoxin treatment." | 3.67 | Interaction study of fenoldopam--digoxin in congestive heart failure. ( Ambrosioni, E; Fuccella, LM; Malini, PL; Pasinelli, F; Riva, E; Strocchi, E; Tartagni, F; Valtancoli, G, 1989) |
| " A daily levodopa dosage of at least 4 g appears to a prerequisite for long-term response to the drug." | 2.38 | Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure. ( Hasenfuss, G; Just, H, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 8 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, JJ | 1 |
| Mitha, AS | 1 |
| Sareli, P | 1 |
| de Vaal, JB | 1 |
| Blanchett, DG | 1 |
| Green, JA | 2 |
| Nara, A | 1 |
| Pospisil, R | 1 |
| Jarvis, RC | 2 |
| Kasmer, RJ | 2 |
| Boyle, DA | 1 |
| Cyronak, MJ | 1 |
| Corder, CN | 1 |
| Girbes, AR | 1 |
| van Veldhuisen, DJ | 1 |
| Smit, AJ | 1 |
| Murphy, MB | 1 |
| Elliott, WJ | 1 |
| Munger, MA | 1 |
| Benotti, JR | 1 |
| Nara, AR | 1 |
| McCue, JE | 1 |
| Pospisil, RA | 1 |
| MacDonald, TM | 1 |
| Jeffrey, RF | 1 |
| Muir, AL | 1 |
| Lee, MR | 1 |
| Holcslaw, TL | 1 |
| Beck, TR | 1 |
| Casagrande, C | 1 |
| Merlo, L | 1 |
| La Regina, A | 1 |
| Hasenfuss, G | 1 |
| Just, H | 1 |
| Strocchi, E | 1 |
| Tartagni, F | 1 |
| Malini, PL | 1 |
| Valtancoli, G | 1 |
| Ambrosioni, E | 1 |
| Pasinelli, F | 1 |
| Riva, E | 1 |
| Fuccella, LM | 1 |
4 reviews available for sk&f-38393 and Cardiac Failure
| Article | Year |
|---|---|
Dopamine and dopamine receptor agonists in cardiovascular therapy.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Biological Availability; Blood Pressure; | 1990 |
Clinical experience with intravenous fenoldopam.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Cardiovascular System; Chemical Phenomen | 1990 |
Development of dopaminergic drugs for the chronic treatment of congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Deoxyepinephrine; Dopamine; Dop | 1990 |
Clinical relevance of long-term therapy with levodopa and orally active dopamine analogues in patients with chronic congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Chronic Disease; D | 1989 |
3 trials available for sk&f-38393 and Cardiac Failure
| Article | Year |
|---|---|
Intravenous fenoldopam infusion in severe heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Diuretics; Dopamine Agents; Dose- | 1993 |
The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Adult; Aged; Biolo | 1991 |
A preliminary study of the dopamine DA1 agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aged; Body Weight; Coronary Disease; Dop | 1990 |
3 other studies available for sk&f-38393 and Cardiac Failure
| Article | Year |
|---|---|
Dopamine agonists, a new perspective in cardiovascular therapy?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Deoxyepinephrine; Dopamine Agents; Fenol | 1991 |
Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Aged, 80 and over; Drug Tol | 1990 |
Interaction study of fenoldopam--digoxin in congestive heart failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Digoxin; Dopamine Agents; D | 1989 |